TEL
AVIV, Israel, Aug. 1, 2022
/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB),
(Chemomab), a clinical stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, today announced the
company will release its second quarter 2022 financial results and
provide a business update on Friday, August
12, 2022 at 8:00 am Eastern
Time.
During the event, Chemomab's management team will review second
quarter 2022 performance, discuss recent and upcoming developments
and conduct a live question-and-answer session.
A replay of the call will be available on Chemomab's website for
90 days at www.chemomab.com.
Live Webcast and Conference Call at 8:00 am Eastern Time, Friday, August 12, 2022
Click this Webcast link to access the live webcast or
replay.
The live webcast and replay can also be accessed at the News
& Events section of the Investors page on
the Chemomab website
at investors.chemomab.com/events.
Conference Call Access via Telephone
US Investors:
+1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference Passcode: 13730646
Please call 5-10 minutes before the scheduled start time, enter
the conference passcode and ask the operator for the Chemomab
conference call.
About Chemomab
Therapeutics
Chemomab is a clinical stage biotechnology company focusing
on the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to begin in late 2022. For more information,
visit chemomab.com.
Contacts:
Investor
Relations:
|
Media:
|
Irina Koffler
|
Barbara Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President
|
ir@chemomab.com
|
Investor &
Public Relations,
|
|
Strategic
Communications
|
|
Phone: +1 (917)
355-9234
|
|
barbara@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-a-business-update-301596618.html
SOURCE Chemomab Therapeutics, Ltd.